Contributed article · Express Pharma
From capacity to capability: Five proofs for India’s pharma future
Varun Sharma · AuthorPress room.
Source-linked material for accurate coverage.
Biographies, verifiable facts, current roles, reference images and a classified publication record. Earlier publisher bylines are mapped on the evidence-indexed biography.
Latest publication record · October 2026
Medicines, AI and the work ahead.
Listen, read the original context, then keep the publication boundary visible. None of these records is a partnership, endorsement or product-readiness assessment.
Biographies
Select length
Varun Sharma runs NEUVIOR and VARUNÉ Bio, working across medicines, biomedical research, and formulation science. He is CEO and CTO of NEUVIOR and product architect of PHARMORIS. NEUVIOR works across medicines intelligence, biomedical research and resource economics, alongside its Constellation scientific destinations concept. VARUNÉ Bio pursues cosmetic formulation and ingredient research. Each company retains its own scientific record, responsibilities and development stage.
Quick facts
- Public name
- Varun Sharma
- Current roles
- Founder, NEUVIOR and VARUNÉ Bio
CEO & CTO, NEUVIOR
Product architect, PHARMORIS - Base
- United Kingdom
- Focus
- Medicines systems, responsible AI and accountable innovation
- Innovation-support boundary
- NEUVIOR has been selected for non-dilutive support for defined R&D project work. This site links only project-level information already in the public domain. Maximum award value, eligible project cost, company contribution and cash received are different facts; Award ceilings and eligible project costs are not cash received, revenue, customer adoption or outcomes.
- Name note
- Use Varun Sharma in current coverage, titles and metadata. Earlier publisher bylines are mapped on the evidence-indexed biography.
Reference image downloads
Available for reference. Confirm usage terms before publication.
Portrait
Download high resolutionImage usage notes
Formal portrait 2026
Download high resolutionImage usage notesComplete publication record
Publication record. Exact labels.
Publisher names identify linked records. Access notes, historical-name attributions and derivative relationships appear where they change how a record should be read.
Outlet names identify publishers of the linked records. Their inclusion does not imply endorsement, sponsorship, partnership or approval.
Commentary, letters and appearances
Written by Varun, featuring him, or built around his attributable contribution. These are not presented as independent reporting.
Contributed articleExpress PharmaFrom capacity to capability: Five proofs for India’s pharma futureBy Varun SharmaContributed commentary; the original article is available from Express Pharma.Podcast appearance
AI Ethics Now · University of Warwick IATLAI and Accountability: When Does a Suggestion Become a Decision?Guest: Varun SharmaPodcast participation does not imply University of Warwick endorsement, partnership or product assessment.Contributed views and analysis
pharmaphorumApproval is not access: Pilots’ real test is implementationBy Varun SharmaContributed analysis, not independent reporting about NEUVIOR or evidence of PHARMORIS adoption.Contributed opinion
TechRadar ProFive questions to test whether an AI stack is truly under your controlBy Varun SharmaContributed opinion; publication is not independent validation of NEUVIOR or its systems.Contributed commentary
ETPharmaIndia’s pharma quality reset will be won after the inspector leavesBy Varun Sharma · May prompt for sign-inPublished letter
Financial TimesLetter: The real test is whether invention leads to adoptionEarlier publisher byline; identity mapping is documented on the biography page · Subscriber accessExpert commentary
Pharmaceutical TechnologyWhy the India-UK trade deal now needs a five-gate implementation ledgerCommentary from Varun Sharma; page byline Ross LawMagazine commentary
PharmaTimesHow we rollEarlier publisher byline; identity mapping is documented on the biography pageContributed commentary
Manufacturing ChemistNICE approval is not enough: why the UK’s next medicines challenge is operational deliverySubscriber access beyond the extractContributed commentary
Startups MagazineWhat my dad’s corner shop taught meBy Varun SharmaContributed commentary
BusinessCloudWhy neurodivergent founders can excel at building complex systemsBy Varun Sharma
Express PharmaFrom capacity to capability: Five proofs for India’s pharma futureBy Varun SharmaContributed commentary; the original article is available from Express Pharma.Podcast appearanceAI Ethics Now · University of Warwick IATLAI and Accountability: When Does a Suggestion Become a Decision?Guest: Varun SharmaPodcast participation does not imply University of Warwick endorsement, partnership or product assessment.Contributed views and analysispharmaphorumApproval is not access: Pilots’ real test is implementationBy Varun SharmaContributed analysis, not independent reporting about NEUVIOR or evidence of PHARMORIS adoption.Contributed opinionTechRadar ProFive questions to test whether an AI stack is truly under your controlBy Varun SharmaContributed opinion; publication is not independent validation of NEUVIOR or its systems.Contributed commentaryETPharmaIndia’s pharma quality reset will be won after the inspector leavesBy Varun Sharma · May prompt for sign-inPublished letterFinancial TimesLetter: The real test is whether invention leads to adoptionEarlier publisher byline; identity mapping is documented on the biography page · Subscriber accessExpert commentaryPharmaceutical TechnologyWhy the India-UK trade deal now needs a five-gate implementation ledgerCommentary from Varun Sharma; page byline Ross LawMagazine commentaryPharmaTimesHow we rollEarlier publisher byline; identity mapping is documented on the biography pageContributed commentaryManufacturing ChemistNICE approval is not enough: why the UK’s next medicines challenge is operational deliverySubscriber access beyond the extractContributed commentaryStartups MagazineWhat my dad’s corner shop taught meBy Varun SharmaContributed commentaryBusinessCloudWhy neurodivergent founders can excel at building complex systemsBy Varun SharmaReporting and project coverage
Publisher-written reports, news briefs and project-centre coverage. Multiple outlets may cover the same underlying event.
Quoted contributionBeautyMatterHow Beauty Can Make Watertight Claims from Lab to ShelfBy Kacey Culliney. Varun Sharma is quoted; the publisher uses the VARUNÉ Labs name. Bio remains a separate company.Publisher-written project coverage
Insider MediaBusiness secures Innovate UK award for pharmaceutical manufacturing waste projectBy Stephen FarrellPublisher-written news brief
Digital HealthDigital Health Coffee Time Briefing ☕Roundup item mentioning NEUVIOR.Publisher-written news brief
Daily BusinessStats US growth, Neuvior funds, Balmoral Comtec soldEarlier publisher attribution; identity mapping is documented on the biography pageMulti-story roundup; part of the Scottish Enterprise funding coverage cluster.Publisher-written funding coverage
TheBusinessDesk.comGlasgow pharmatech start-up backed by Scottish EnterpriseRegistration-meteredProject coverage
Biorenewables Development CentreNEUVIOR advances ZYLON programme following Innovate UK awardProject-centre publication; not presented as independent media reporting.Publisher-written project coverage
The Yorkshire PostNeuvior wins grant to tackle pharmaceutical sector waste with York schemeEarlier publisher attribution; identity mapping is documented on the biography pagePublisher-written project coverage
York PressNEUVIOR Pharmaceuticals new sustainable drug trialsEarlier publisher attribution; identity mapping is documented on the biography page
Insider MediaBusiness secures Innovate UK award for pharmaceutical manufacturing waste projectBy Stephen FarrellPublisher-written news briefDigital HealthDigital Health Coffee Time Briefing ☕Roundup item mentioning NEUVIOR.Publisher-written news briefDaily BusinessStats US growth, Neuvior funds, Balmoral Comtec soldEarlier publisher attribution; identity mapping is documented on the biography pageMulti-story roundup; part of the Scottish Enterprise funding coverage cluster.Publisher-written funding coverageTheBusinessDesk.comGlasgow pharmatech start-up backed by Scottish EnterpriseRegistration-meteredProject coverageBiorenewables Development CentreNEUVIOR advances ZYLON programme following Innovate UK awardProject-centre publication; not presented as independent media reporting.Publisher-written project coverageThe Yorkshire PostNeuvior wins grant to tackle pharmaceutical sector waste with York schemeEarlier publisher attribution; identity mapping is documented on the biography pagePublisher-written project coverageYork PressNEUVIOR Pharmaceuticals new sustainable drug trialsEarlier publisher attribution; identity mapping is documented on the biography pageInternational follow-on publications
Republication-style or AI-produced derivatives of the five-gate commentary, retained for transparency and not counted as separate original articles.
Publication is evidence of publication. It is not proof of deployment, endorsement, customer adoption or commercial outcome.
Media enquiry
Working to a deadline?
Include your outlet, topic and publication date so the request can be prioritised.
Prepare a media enquiry
Use the same address for fact checks, corrections and image permissions.